Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
- Conditions
- Wound HealingMohs Micrographic Surgery
- Interventions
- Other: Standard of Care
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 102
- Registration Number
- NCT06941467
- Locations
- 🇺🇸
Mount Sinai, New York, New York, United States
Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Auson Pharmaceuticals Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06824948
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Timolol Maleate Gel for the Treatment of Infantile Hemangioma
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Auson Pharmaceuticals Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06677853
- Locations
- 🇨🇳
Beijing Children's Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Children's Hospital, Capital Institute of Pediatrics, Beijing, Beijing, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
- Conditions
- ParonychiaEGFR-TKIALK-TKI
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Queen Mary Hospital, Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT06643416
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06152861
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Newport Beach, California, United States
Efficacy and Safety of Timolol for TKI Induced Paronychia
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Queen Mary Hospital, Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT06140186
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
- Conditions
- Ocular HypertensionGlaucomaCataract
- Interventions
- Device: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOLDevice: SpyGlass IOL
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- SpyGlass Pharma, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT06120842
- Locations
- 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionGlaucoma Open-Angle Primary
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- D. Western Therapeutics Institute, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05913232
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
🇺🇸Central Florida Eye Associates, Lakeland, Florida, United States
🇺🇸Shettle Eye Research, Inc., Largo, Florida, United States
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-12-11
- Target Recruit Count
- 174
- Registration Number
- NCT05479123
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study
- Conditions
- Epidermal Growth Factor Receptor InhibitorParonychia
- Interventions
- Procedure: Cryotherapy with liquid nitrogen
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Taipei Medical University WanFang Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT05165082
- Locations
- 🇨🇳
Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.